Background--Magnesium (Mg) has potential hemostatic properties. We sought to investigate the potential association of serum Mg levels (at baseline and at 48 hours) with outcomes in patients with acute spontaneous intracerebral hemorrhage (ICH).
M agnesium (Mg) is a cation with essential roles in normal physiological function. 1 Mg modulates vascular smooth muscle tone, peripheral vascular resistance, and blood flow dynamics. 2 Mg also plays crucial roles in hemostasis by accelerating activation of factor X via factor VII-tissue factor, 3 causing conformational changes in coagulation factor IX 4 that augment its biological activities, 5 potentiating platelet aggregation, 6 and decreasing levels of the intrinsic antithrombotics protein S and C. 6 Clinical applications for Mg on the basis of its hemostatic properties have been proposed. Mg infusion has demonstrated encouraging results in trauma-induced coagulopathy 7, 8 and has been shown to decrease surgical blood loss in patients undergoing microscopic lumbar discectomy. 9 Spontaneous intracerebral hemorrhage (ICH) is the second most common subtype of stroke and leads to severe disability or death. 10 Platelet dysfunction and coagulopathy are major causes of hematoma expansion and mortality in patients with ICH. 10 Mg may have potential therapeutic implications on the basis of its hemostatic properties. A recent retrospective study hypothesized that Mg exerts a clinically meaningful influence on hemostasis in patients with ICH. 11 Another retrospective study showed that low admission Mg levels occurred in one third of patients with ICH and were associated with worse clinical presentation and intraventricular hemorrhage. 12 The relationship between Mg levels, hematoma volume, and clinical outcome in ICH remains unclear because of limited literature. To clarify this relationship, we sought to evaluate the association of serum Mg levels at admission and at 48 hours with clinical and neuroimaging outcomes in patients with acute spontaneous ICH.
Methods
The data that support the findings of this study are available from the corresponding author on reasonable request.
Study Population
We conducted a retrospective analysis of a prospectively collected database of consecutive patients with acute (<24 hours) spontaneous ICH in a tertiary-care stroke center from January 1, 2011 to December 31, 2015, as previously described. [13] [14] [15] Inclusion criteria were as follows: spontaneous cause for ICH, adult age (>18 years old), and available serum Mg level at admission. Exclusion criteria were as follows: nonspontaneous causes of ICH (including traumatic ICH, metastatic hemorrhagic cerebral lesions, ICH resulting from venous sinus thrombosis, and ICH resulting from underlying vascular lesions), ICH attributable to supratherapeutic international normalized ratio in the setting of prehospital anticoagulation or coagulopathy (threshold international normalized ratio of 1.5), 16 and thrombocytopenia (platelets <50 000/mm 3 ). 13, 14 Per hospital protocol, all patients with ICH were initially admitted to the intensive care unit. Target systolic blood pressure goal was <140 mm Hg during the first 24 hours after admission, achieved with intravenous pushes of enalapril, hydralazine, or labetalol and/or continuous nicardipine infusion. If clinically stable, systolic blood pressure parameters were relaxed to goal <160 mm Hg after 24 to 48 hours of admission, per treating physician's decision. 13, 15 Institutional investigation review board approval for this study was granted on the basis of the acute ICH database. Board waived the need for patient consent.
Baseline Characteristics and Outcome Measures
We obtained demographics, medical history, premorbid modified Rankin Scale (mRS) scores, and baseline radiological and clinical parameters, as previously reported. 13, 14 Baseline severity of neurological dysfunction was documented using National Institutes of Health Stroke Scale (NIHSS) score, whereas baseline severity of ICH was quantified by ICH score, as previously described. [13] [14] [15] Mg levels were obtained within 6 hours of hospitalization, similar to other laboratory values, such as international normalized ratio, glucose, platelets, and lipid levels. In addition, Mg levels were recorded at 48 hours, if available. All patients underwent computed tomography of the head (CTH) at hospital admission. Follow-up CTH was acquired within 6 to 24 hours of initial CTH, as previously described. 15 The clinical and radiological outcome measures included admission hematoma volume (measured using ABC/2 method, as previously described), 13, 17 hematoma expansion (defined as an absolute increase of >12.5 mL or a relative increase of >33% in hematoma volume at the 6-to 24-hour follow-up CTH compared with the admission CTH), 18 admission NIHSS score, admission ICH score, severe neurological dysfunction (defined as NIHSS score >10 points at admission), 19 severe ICH (defined as ICH score >2 points at admission), 18, 19 large hematoma volume (defined as hematoma volume >30 cm 3 ), 18 favorable functional outcome (FFO)
at hospital discharge (defined as mRS scores of 0-1), functional independence (FI; defined as mRS scores of 0-2) at hospital discharge, and in-hospital mortality.
Statistical Analysis
Continuous variables with normal distributions were presented as means with SD, whereas those with skewed distributions were presented as medians with interquartile range. 
Clinical Perspective
What Is New?
• Higher admission serum magnesium levels are associated with lower admission hematoma volume and lower admission intracerebral hemorrhage score in patients with acute spontaneous intracerebral hemorrhage.
• In addition, higher admission serum magnesium levels are associated with higher odds of functional independence and favorable functional outcome at discharge in univariate analyses.
What Are the Clinical Implications?
• The findings of our study are hypothesis generating and require independent confirmation by prospective multicenter studies and potentially in a randomized controlled trial provided our findings are validated by additional, prospective, and larger data sets.
at 48 hours) and admission NIHSS score, admission ICH score, admission hematoma volume, and absolute and relative hematoma increase were evaluated using Spearman's correlation coefficient (r). Simple and multiple linear regression analyses were used to evaluate the associations between baseline characteristics and hematoma volume, square root of NIHSS score, and ICH score. Before simple and multiple linear regression analyses, admission hematoma volume was cube root transformed for each patient to satisfy statistical assumptions about normality of distribution. 20 Similarly, admission NIHSS scores were square transformed for each patient to satisfy statistical assumptions about normality of distribution. 21 In all univariable analyses, a threshold of P<0. Table 2 depicts the association of serum Mg levels (at baseline and at 48 hours) with admission NIHSS score, admission ICH score, and admission hematoma volume. Higher admission Mg levels correlated with lower admission NIHSS score (Spearman's r, À0.141; P=0.015), lower ICH score (Spearman's r, À0.153; P=0.009), and lower initial hematoma volume (Spearman's r, À0.153; P=0.012). There was no correlation (P>0.1) of serum Mg levels at 48 hours with admission NIHSS score, ICH score, and initial hematoma volume. There was no significant correlation of serum Mg levels (at baseline and at 48 hours) with absolute and relative hematoma increase (P>0.1) (Table S1 ). Similarly, we did not document any significant association between serum Mg levels (at baseline and at 48 hours) with severe neurological dysfunction (NIHSS score >10), severe ICH (ICH score >2), large hematoma volume (>30 cm 3 ) , and hematoma expansion (P>0.1) (Table S2 ). In addition, no correlation was noted between admission Mg levels and final ICH volume on followup CT scan (Spearman's r, À0.119; P=0.112).
Univariate associations of serum Mg levels (at baseline and at 48 hours) with discharge functional outcomes are depicted in Table 3 Because the hematoma volume had a skewed distribution (2.112; P<0.001 by 1-sample Kolmogorov-Smirnov test), we used the cube root transformed hematoma volume as the target variable in simple and multiple linear regression models. This transformation reduced the skew of the target variable to 0.317 (P=0.293 by 1-sample KolmogorovSmirnov test; Table S3 ). Associations between clinical and radiographic variables and the cubed root of hematoma volume at admission are presented in Table 4 . Several demographic variables were associated with cubed root of hematoma volume on simple linear regression analysis: black race, history of hyperlipidemia, history of chronic kidney disease, lobar location for ICH, intraventricular location for ICH, and serum Mg levels at admission. Increasing admission Mg level (per 0.1-mg/dL increase) was negatively correlated with admission hematoma volumes (simple linear regression coefficient, À0.024; 95% CI, À0.044 to À0.003; P=0.026). Multiple linear regression analyses identified the following independent predictors of admission hematoma volume: black race, history of hyperlipidemia, lobar location for ICH, intraventricular location for ICH, and admission serum Mg levels. More specifically, a 0.1-mg/dL increase in admission serum Mg levels was independently and negatively associated with the cubed root of hematoma volume (multiple linear regression coefficient, À0.020; 95% CI, À0.040 to À0.000; P=0.049) after adjusting for potential confounders.
Because the NIHSS score inherently has a skewed distribution (skewness, 0.937; P<0.001 by 1-sample Kolmogorov-Smirnov test), we used the square root transformed NIHSS as the target variable in multiple linear regression models. This transformation reduced the skew of the target variable to 0.055 (P=0.056 by 1-sample Kolmogorov-Smirnov test; Table S3 ).
Associations between clinical and radiographic variables and the square root of admission NIHSS score are shown in Table S4 . A 0.1-mg/dL increase in admission Mg levels was negatively correlated with admission NIHSS score in simple linear regression analysis (linear regression coefficient, À0.073; 95% CI, À0.141 to À0.006; P=0.034); however, this association did not retain its significance in multiple linear regression model after adjustment for potential confounders (multiple linear regression coefficient, 0.040; 95% CI, À0.099 to 0.020; P=0.189). The following 4 variables emerged as independent (P<0.05) predictors of admission NIHSS score in multiple linear regression analyses: body mass index, hyperlipidemia, admission serum glucose, and intraventricular extension of ICH.
Associations between clinical and radiographic variables and admission ICH score are shown in Table 5 . The following variables were associated with ICH score on simple linear regression analyses: body mass index, history of hypertension, history of hyperlipidemia, admission serum glucose, admission systolic blood pressure, admission diastolic blood pressure, and admission serum Mg. Multiple linear regression analyses identified the following independent predictors of admission ICH score: body mass index, history of hypertension, history of hyperlipidemia, admission serum glucose level, and admission serum Mg level. More specifically, a 0.1-mg/dL increase in admission serum Mg levels was independently and 
Discussion
Our study shows that higher admission serum Mg levels were independently associated with lower admission hematoma volume and lower admission ICH score in patients with acute spontaneous ICH. In addition, higher admission serum Mg levels were associated with higher odds of FI and FFO at discharge in univariate analyses. However, these associations failed to reach significance in multivariate models. It is plausible that the potential beneficial effects of admission Mg levels on functional outcomes may be mediated through an independent impact of Mg on ICH score and hematoma volume, because increasing ICH score and increasing hematoma volume emerged as independent predictors of poor functional outcomes at hospital discharge.
Our findings are partially in line with the observations of Liotta et al, who reported an independent association of lower admission Mg levels with larger initial hematoma volumes and worse functional outcomes at 3 months. 11 However, there are important methodological considerations when comparing the 2 studies. First, our study excluded ICH caused by coagulopathy. In contrast, Liotta et al evaluated a sample in which 22.1% of patients had some form of underlying coagulopathy.
11
It is likely that patients with ICH with underlying coagulopathy received some form of hemostatic treatment in their study (ie, plasma or factor concentrates), which may have confounded the potential influence of Mg on hemostasis. Second, we also evaluated follow-up serum Mg levels at 48 hours, which was not done by Liotta et al. 11 We did not detect any association between serum Mg levels at 48 hours and any of the outcome variables. This observation may indicate that the influence of Mg on hemostasis is maximal in the first few hours after ICH ictus, when the possibility of hematoma expansion and neurological injury are highest. Alternatively, a lack of observed association may simply be type II error because of limited sample size, because followup Mg levels were not available in the entire study population. Finally, the 2 studies differed in the duration of follow-up, because we were unable to evaluate the functional status of our patients at 3 months, whereas Liotta et al 11 assessed mRS scores at 3 months. Another indication of the potential hemostatic property of Mg comes from the FAST-MAG (Field Administration of Stroke Therapy-Magnesium) trial, in which prehospital infusion of Mg sulfate was administered to patients with acute stroke 23 Although this trial failed to show any improvement in outcome at 90 days, the rate of symptomatic hemorrhagic transformation after ischemic stroke tended to be nonsignificantly lower in the group that received prehospital Mg sulfate (2.1% versus 3.3%; P=0.12), indicating a possible hemostatic effect of Mg.
11,23
The univariate association of higher Mg levels with improved functional outcomes at hospital discharge cannot be attributed to a potential decrease in hematoma expansion because serum Mg levels at admission and at 48 hours did not correlate with hematoma expansion in our cohort. This could imply that, in addition to influencing hemostasis, Mg might have possible neuroprotective effects for patients with ICH. 24 Preclinical data suggest that Mg exhibits multiple complementary neuroprotective mechanisms, including inhibition of glutamate release, 25 restoration of blood-brain barrier integrity, decrease in brain edema, 26 and noncompetitive antagonism of N-methyl-D-aspartate receptor activation via blockage of voltage-dependent calcium channels. 24, 27 Moreover, the antihypertensive effect of Mg could be protective in patients with ICH. 24 Two randomized studies have examined the effects of short-term Mg infusion in patients experiencing acute stroke. 23, 28 A total of 168 (8.3% of the total enrolled patients) patients with acute ICH were infused with Mg or placebo before brain imaging in the IMAGES (Intravenous Magnesium Efficacy in Stroke) trial. 28 The point estimate of treatment effect quantified as reduction in death or disability was favorable (OR, 0.84; 95% CI, 0.41-1.74) in this cohort, although the sample size of patients with ICH was small to 24, 28 Similarly, in the FAST-MAG trial, no outcome benefit was documented with prehospital Mg infusion in the subset of patients with ICH (n=195). 23 Some explanations may be considered for the observed lack of association in both trials. First, both studies were not designed to evaluate the protective effect of Mg infusion in patients with ICH. 23, 28 Second, baseline Mg levels were unknown in both studies, and it is possible that the potential hemostatic and neuroprotective effects of Mg may be exerted only in patients with low serum Mg levels.
11
Several limitations in our study should be noted. First, the modest sample size and retrospective analysis of prospectively collected data are important methodological shortcomings. Second, clinical outcomes (mRS score and mortality) were evaluated at discharge and not in a prolonged subacute time frame (3 months) that maximizes clinical recovery after ICH. However, as we reported previously, 13,14 a subsequent 3-month follow-up evaluation would have likely improved functional outcome but would likely reflect clinical improvements made after rehabilitation and physical therapy. Third, 48-hour serum Mg levels were not available in our entire study population. In our cohort, we did not see any correlation between Mg levels at 48 hours and any of the outcome variables. Nevertheless, this lack of association may be attributed to type II error because of limited sample size (n=191). Fourth, the possibility of residual confounding factor affecting the results cannot be ruled out completely. Fifth, our data allowed us to detect only a statistical association between Mg levels and outcomes in patients with acute spontaneous ICH. The observational study design did not allow us to establish a cause-effect relationship between baseline serum Mg levels and outcome measures in patients with ICH. Sixth, we only included patients with spontaneous ICH in the present study, considering the fact that patients with ICH with associated coagulopathy and/or trauma are frequently on anticoagulation and receive hemostatic treatment in form of factor concentrates or plasma in the emergency department. We believe that hemostatic treatment would be a major confounding factor while evaluating the potential hemostatic property of Mg in patients with ICH. Seventh, the ABC/2 score accurately estimates hematoma volume in cases of round-to-ellipsoid shape of the hematoma and overestimates volume in irregular and separated shapes. 29 However, separated and irregular hematoma shapes occur more frequently in oral anticoagulation therapy-related ICHs, 29 and we did not include ICH caused by coagulopathy in our cohort. Eighth, we included patients with acute ICH presenting within 24 hours of symptom onset in our study. However, the time between symptom onset and brain CT was not recorded, which did not allow us to account for the effect of presentation to scan time on different outcomes variables while evaluating the hemostatic properties of Mg. Ninth, the possibility of type I error attributable to multiple comparisons needs to be taken into account in the interpretation of our results. Finally, the findings of our study are hypothesis generating and require independent confirmation by prospective multicenter studies and potentially in a randomized controlled trial provided our findings are validated by additional, prospective, and larger data sets.
In conclusion, our study demonstrates that higher admission serum Mg levels may be associated with smaller initial hematoma volume and lower admission ICH score in patients with acute spontaneous ICH. Future multicenter randomized controlled clinical trials are needed to explore potential therapeutic implications of Mg infusion in patients with acute ICH with lower admission Mg levels. 
